Menu Search
Equities

QuantumPharm Inc

QNTPF:PKC

QuantumPharm Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

QuantumPharm Inc is a China-based company principally engaged in the provision of drug discovery solutions and intelligent automation solutions. The Company operates its businesses through two segments. The Drug Discovery Solutions segment spans the full spectrum of the drug discovery and research process, providing modular standalone solutions to or collaborating with a diverse range of biotechnology and pharmaceutical companies and academic institutions for novel drug discovery endeavors. The Intelligent Automation Solutions segment includes solid-state research and development services and automated chemical synthesis services. Solid-state research and development services include computing services, wet laboratory services and comprehensive solutions.

  • Revenue in HKD (TTM)211.71m
  • Net income in HKD-2.73bn
  • Incorporated2017
  • Employees760.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.